文献速递慢阻肺

罗氟司特在重度慢阻肺中应答决定因素的汇总分析

Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该预设汇总分析纳入REACT和RE2SPOND两项随机双盲安慰剂对照研究,共4287例重度慢阻肺患者,评估罗氟司特减少急性加重的作用。结果显示罗氟司特显著降低中重度急性加重12.3%和重度急性加重16.1%,在既往因急性加重住院、频繁急性加重或血嗜酸性粒细胞≥150 cells/μl的患者中获益更明显。

要点

  • 罗氟司特降低重度慢阻肺患者中重度急性加重12.3%,重度急性加重16.1%。
  • 既往因急性加重住院者获益最大,中重度急性加重风险比0.74。
  • 基线血嗜酸性粒细胞≥150 cells/μl者中重度急性加重风险比0.81。

核心结论

  • 罗氟司特可减少重度慢阻肺患者急性加重,在既往住院、频繁急性加重或血嗜酸性粒细胞≥150 cells/μl者中获益更显著。

研究设计与样本

  • REACT和RE2SPOND两项多中心随机双盲安慰剂对照研究的预设汇总分析,意向治疗人群n=4287。

主要发现

  • 总体人群中,罗氟司特较安慰剂降低中重度急性加重12.3%(率比0.88,95%CI 0.80-0.97,P=0.0086),降低重度急性加重16.1%(0.84,0.71-0.99,P=0.0409)。
  • 既往因急性加重住院者中重度急性加重率比0.74(0.63-0.88,P=0.0005);既往一年急性加重>2次者率比0.79(0.65-0.96,P=0.0160)。
  • 基线血嗜酸性粒细胞≥150 cells/μl者中重度急性加重率比0.81(0.71-0.93,P=0.0020),≥150至<300 cells/μl者0.84(0.71-0.98,P=0.0282),≥300 cells/μl者0.77(0.61-0.97,P=0.0264)。
  • 既往住院且血嗜酸性粒细胞≥150 cells/μl者中重度急性加重降低34.5%(0.65,0.52-0.82,P=0.0003),≥300 cells/μl者降低42.7%(0.57,0.37-0.88,P=0.0111)。

临床怎么用

  • 对既往因急性加重住院、频繁急性加重或血嗜酸性粒细胞≥150 cells/μl的重度慢阻肺患者,可考虑罗氟司特以减少急性加重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of exacerbations. Further characterization of patients most likely to benefit is warranted. OBJECTIVES: Define characteristics that most robustly identify patients who derive greatest exacerbation risk reduction with roflumilast. METHODS: Predefined, pooled analyses of REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment; NCT01329029) and RE2SPOND (Roflumilast Effect on Exacerbations in Patients on Dual [LABA/ICS] Therapy; NCT01443845) multicenter, randomized, double-blind, placebo-controlled studies. The primary endpoint was rate of moderate or severe exacerbations per patient per year. MEASUREMENTS AND MAIN RESULTS: In the overall intention-to-treat population (n = 4,287), roflumilast reduced moderate or severe exacerbations by 12.3% (rate ratio, 0.88, 95% confidence interval, 0.80-0.97; P = 0.0086) and severe exacerbations by 16.1% (0.84; 0.71-0.99; P = 0.0409) versus placebo. The reduction in moderate or severe exacerbations with roflumilast was most pronounced in patients who had been hospitalized for an exacerbation in the prior year (0.74; 0.63-0.88; P = 0.0005); had more than two exacerbations in the prior year (0.79; 0.65-0.96; P = 0.0160); or had baseline eosinophils ≥150 cells/μl (0.81; 0.71-0.93; P = 0.0020), ≥150 to <300 cells/μl (0.84; 0.71-0.98; P = 0.0282), or ≥300 cells/μl (0.77; 0.61-0.97; P = 0.0264). Similar subgroup results were noted for severe exacerbations. In patients with prior hospitalization and higher baseline blood eosinophil concentrations, roflumilast reduced moderate or severe exacerbations by 34.5% at ≥150 cells/μl (0.65; 0.52-0.82; P = 0.0003) and 42.7% at ≥300 cells/μl (0.57; 0.37-0.88; P = 0.0111) versus placebo. CONCLUSIONS: This prespecified, pooled analysis confirms the benefit of roflumilast in decreasing exacerbations in patients with prior hospitalization for exacerbation, greater exacerbation frequency, and higher (≥150 cells/μl, ≥150 to <300 cells/μl, or ≥300 cells/μl) baseline blood eosinophil count.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Martinez FJ, Rabe KF, Calverley PMA, et al. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. Am J Respir Crit Care Med. 2018. PMID: 29763572. doi:10.1164/rccm.201712-2493OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。